sorafenib [Sorafenib]
- Termíny
-
BAY 43-9006
Nexavar
pyridin-N-oxid
sorafenib tosylát
-
4-(4-(3-(4-Chloro-3-trifluoromethylphenyl)ureido)phenoxy)pyridine-2-carboxylic acid methyamide-4-methylbenzenesulfonate
BAY 43-9006
BAY 545-9085
BAY-545-9085
BAY-673472
Nexavar
Sorafenib N-Oxide
Sorafenib Tosylate
A niacinamide and phenylurea derivative that inhibits multiple intracellular and cell surface kinases thought to be involved in ANGIOGENESIS, including RAF KINASES and VEGF RECEPTORS. It is used in the treatment of advanced RENAL CELL CARCINOMA and HEPATOCELLULAR CARCINOMA, and for treatment of THYROID CARCINOMA refractory to radioactive iodine therapy.
- DUI
- D000077157 MeSH Prohlížeč
- CUI
- M0446095
- RN
- 9ZOQ3TZI87
- CAS
- 2-Pyridinecarboxamide, 4-(4-((((4-chloro-3-(trifluoromethyl)phenyl)amino)carbonyl)amino)phenoxy)-N-methyl-
- Historická pozn.
- 2019 (2003)
- Veřejná pozn.
- 2019; SORAFENIB was indexed under NIACINAMIDE and PHENYLUREA COMPOUNDS 2014-2018, and under BENZENESULFONATES and PYRIDINES 2003-2013
Povolená podhesla
- AG
- agonisté 0
- AA
- analogy a deriváty 0
- AN
- analýza 0
- AI
- antagonisté a inhibitory 0
- AD
- aplikace a dávkování 13
- CS
- chemická syntéza 0
- CH
- chemie 0
- HI
- dějiny 0
- EC
- ekonomika 0
- PK
- farmakokinetika 2
- PD
- farmakologie 12
- IM
- imunologie 0
- IP
- izolace a purifikace 0
- CL
- klasifikace 0
- BL
- krev 0
- ME
- metabolismus 0
- UR
- moč 0
- CF
- mozkomíšní mok 0
- ST
- normy 0
- PO
- otrava 0
- AE
- škodlivé účinky 6
- TU
- terapeutické užití 22
- TO
- toxicita 0
- RE
- účinky záření 0
- SD
- zásobování a distribuce 0